Infusion reactions to rituximab administration: algorithm of management

Authors

DOI:

https://doi.org/10.22141/2307-1257.11.2.2022.364

Keywords:

allergic infusion reactions, rituximab, omalizumab, control of infusion reactions

Abstract

Background. Allergic reactions to rituximab, which have been used for the past 20 years, are common in 32–62 % of patients. The purpose of the study: to develop an algorithm for controlling adverse reactions that occur during the introduction of rituximab. Materials and methods. The personal experience of treatment of 46 patients with various kidney diseases who received rituximab according to the indications according to the established diagnosis was analyzed. Evaluation of infusion allergic reactions was performed according to P.М. Kasi et al. (2012) for 5 classes of side effects. Results. It was found that allergic reactions to ritu­ximab occurred in 46 % of patients in the range from 1 to 4 classes. The probability of their occurrence according to the class was almost the same, but somewhat less documented for the 4th grade. Re-administration of diphenhydramine, methylprednisolone 125 mg or hydrocortisone 125 mg, if necessary salbutamol, oxygen allowed to eliminate most of the reaction, and then resumed the introduction of rituximab, starting from 25 mg/h, gradually increasing to 300 mg/h. This administration, performed 1–2 times, was effective in 1–3 classes of allergic reactions. For fourth grade, one patient required omalizumab. Generalized experience allowed to give a graphical and descriptive algorithm of actions in case of infusion side effects for rituximab. Conclusions. Based on special data and literature analysis, an algorithm for controlling infusion allergic reactions with intravenous rituximab was formulated.

Downloads

Download data is not yet available.

References

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021.

Ivanov DD, Dyadyk OO, Rotova SO, Ivanovа MD. 10-year personal experience of rituximab use in nephrological patients. Počki. 2020;9(2):99-104. doi:10.22141/2307-1257.9.2.2020.203409. (in Ukrainian).

Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care. 2012 Aug 31;16(4):231. doi:10.1186/cc11304.

Rituxim: instructions for the medical use. Available from: https://likicontrol.com.ua/%D1%96%D0%BD%D1%81%D1%82%D1%80%D1%83%D0%BA%D1%86%D1%96%D1%8F/?[20666].

Online Calculators. Available from: https://www.gigacalculator.com/calculators/.

Ivanov DD, Mordovec EM, Tikhonenko NO, Tomin KV. Lupus nephritis: experience of treatment with rituximab (clinical observation). Počki. 2012;(2):68-70. doi:10.22141/2307-1257.0.2.2012.176616. (in Ukrainian).

Vanholder R, De Weggheleire A, Ivanov DD, et al. Continuing kidney care in conflicts. Nat Rev Nephrol. 2022 May 30. doi:10.1038/s41581-022-00588-7.

Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006 Sep;54(9):2793-2806. doi:10.1002/art.22025.

Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006 May;54(5):1390-1400. doi:10.1002/art.21778.

Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998 Sep 15;92(6):1927-1932.

Farzadfard F, Poursadeghfard M, Ashjazadeh N. Infusion-Related, Short-term, and Delayed Side Effects of Rituximab in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Shiraz E-Med J. 2020;22(3):e101625. doi:10.5812/semj.101625.

Airas L, Nylund M, Mannonen I, Matilainen M, Sucksdorff M, Rissanen E. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland. Mult Scler Relat Disord. 2020 May;40:101980. doi:10.1016/j.msard.2020.101980.

Shaygannejad V, Fayyazi E, Badihian S, et al. Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study. J Neurol. 2019 Mar;266(3):642-650. doi:10.1007/s00415-019-09180-9.

Klomjit N, Fervenza FC, Zand L. Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases. Am J Kidney Dis. 2020 Dec;76(6):883-888. doi:10.1053/j.ajkd.2020.02.444.

Published

2022-07-13

How to Cite

Ivanov, D., & Zavalna, I. (2022). Infusion reactions to rituximab administration: algorithm of management. KIDNEYS, 11(2), 81–85. https://doi.org/10.22141/2307-1257.11.2.2022.364

Issue

Section

Cover story

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>